$8.48
-0.21-2.36%
At Close: -
$8.47
-0.01-0.18%
After Hours: Jul 19, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Terns Pharma
TERNNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Terns Pharma (NASDAQ:TERN) Stock, Analyst Ratings, Price Targets, Forecasts
Terns Pharmaceuticals Inc has a consensus price target of $14.83 based on the ratings of 9 analysts. The high is $23 issued by Roth MKM on August 8, 2023. The low is $5.5 issued by HC Wainwright & Co. on May 14, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., JMP Securities, and HC Wainwright & Co. on May 14, 2024, April 30, 2024, and April 30, 2024, respectively. With an average price target of $8.67 between HC Wainwright & Co., JMP Securities, and HC Wainwright & Co., there's an implied 2.32% upside for Terns Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JMP Securities
UBS
BMO Capital
Mizuho
1calculated from analyst ratings
Analyst Ratings for Terns Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2024 | Buy Now | -35.06% | HC Wainwright & Co. | Ed Arce | → $5.5 | Reiterates | Neutral → Neutral | Get Alert |
| 04/30/2024 | Buy Now | 77.1% | JMP Securities | Silvan Tuerkcan | → $15 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/30/2024 | Buy Now | -35.06% | HC Wainwright & Co. | Ed Arce | → $5.5 | Reiterates | Neutral → Neutral | Get Alert |
| 03/27/2024 | Buy Now | 112.51% | UBS | Eliana Merle | $19 → $18 | Maintains | Buy | Get Alert |
| 03/18/2024 | Buy Now | 77.1% | JMP Securities | Silvan Tuerkcan | $17 → $15 | Maintains | Outperform | Get Alert |
| 03/15/2024 | Buy Now | -35.06% | HC Wainwright & Co. | Ed Arce | → $5.5 | Reiterates | Neutral → Neutral | Get Alert |
| 03/15/2024 | Buy Now | 124.32% | BMO Capital | Etzer Darout | $18 → $19 | Maintains | Outperform | Get Alert |
| 01/10/2024 | Buy Now | -35.06% | HC Wainwright & Co. | Ed Arce | $8 → $5.5 | Maintains | Neutral | Get Alert |
| 12/05/2023 | Buy Now | 100.71% | JMP Securities | Silvan Tuerkcan | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/27/2023 | Buy Now | 18.06% | Mizuho | Graig Suvannavejh | $17 → $10 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | -5.55% | HC Wainwright & Co. | Ed Arce | $11 → $8 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | 29.87% | JP Morgan | Eric Joseph | $10 → $11 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | 171.55% | Roth MKM | Dylan Dupuis | → $23 | Reiterates | → Buy | Get Alert |
| 07/26/2023 | Buy Now | 100.71% | JMP Securities | Silvan Tuerkcan | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/30/2023 | Buy Now | 171.55% | Roth MKM | Dylan Dupuis | → $23 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | Buy Now | 100.71% | JMP Securities | Silvan Tuerkcan | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/30/2023 | Buy Now | 88.9% | Mizuho | Graig Suvannavejh | → $16 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2023 | Buy Now | 88.9% | Mizuho | Graig Suvannavejh | → $16 | Reiterates | Buy → Buy | Get Alert |
| 06/22/2023 | Buy Now | 88.9% | Mizuho | Graig Suvannavejh | → $16 | Initiates | → Buy | Get Alert |
| 06/07/2023 | Buy Now | 112.51% | Jefferies | Akash Tewari | → $18 | Initiates | → Buy | Get Alert |
| 05/31/2023 | Buy Now | 171.55% | Roth MKM | Dylan Dupuis | → $23 | Initiates | → Buy | Get Alert |
| 05/19/2023 | Buy Now | 29.87% | HC Wainwright & Co. | Ed Arce | → $11 | Reiterates | Neutral → Neutral | Get Alert |
| 05/16/2023 | Buy Now | 18.06% | JP Morgan | Eric Joseph | $9 → $10 | Maintains | Neutral | Get Alert |
| 05/16/2023 | Buy Now | 100.71% | JMP Securities | Silvan Tuerkcan | $17 → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/08/2023 | Buy Now | 112.51% | BMO Capital | Etzer Darout | → $18 | Initiates | → Outperform | Get Alert |
| 03/29/2023 | Buy Now | 100.71% | JMP Securities | Silvan Tuerkcan | → $17 | Reiterates | → Market Outperform | Get Alert |
| 03/29/2023 | Buy Now | 6.26% | JP Morgan | Eric Joseph | $6 → $9 | Maintains | Neutral | Get Alert |
| 03/29/2023 | Buy Now | 29.87% | HC Wainwright & Co. | Ed Arce | $7 → $11 | Maintains | Neutral | Get Alert |
| 02/14/2023 | Buy Now | 100.71% | JMP Securities | Silvan Tuerkcan | → $17 | Initiates | → Market Outperform | Get Alert |
| 02/07/2023 | Buy Now | 124.32% | UBS | Eliana Merle | → $19 | Initiates | → Buy | Get Alert |
| 12/29/2022 | Buy Now | -17.36% | HC Wainwright & Co. | Ed Arce | $6 → $7 | Maintains | Neutral | Get Alert |
| 12/20/2022 | Buy Now | 65.29% | Goldman Sachs | Corinne Jenkins | $9 → $14 | Maintains | Buy | Get Alert |
| 09/28/2022 | Buy Now | 6.26% | Goldman Sachs | Corinne Jenkins | $4 → $9 | Maintains | Buy | Get Alert |
| 09/12/2022 | Buy Now | -29.16% | HC Wainwright & Co. | Ed Arce | → $6 | Initiates | → Neutral | Get Alert |
| 03/23/2022 | Buy Now | -29.16% | JP Morgan | Eric Joseph | $19 → $6 | Downgrade | Overweight → Neutral | Get Alert |
| 08/18/2021 | Buy Now | 124.32% | JP Morgan | Eric Joseph | $32 → $19 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Terns Pharma (TERN) stock?
The latest price target for Terns Pharma (NASDAQ:TERN) was reported by HC Wainwright & Co. on May 14, 2024. The analyst firm set a price target for $5.50 expecting TERN to fall to within 12 months (a possible -35.06% downside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Terns Pharma (TERN)?
The latest analyst rating for Terns Pharma (NASDAQ:TERN) was provided by HC Wainwright & Co., and Terns Pharma reiterated their neutral rating.
When was the last upgrade for Terns Pharma (TERN)?
There is no last upgrade for Terns Pharma
When was the last downgrade for Terns Pharma (TERN)?
The last downgrade for Terns Pharmaceuticals Inc happened on March 23, 2022 when JP Morgan changed their price target from $19 to $6 for Terns Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Terns Pharma (TERN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Terns Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Terns Pharma was filed on May 14, 2024 so you should expect the next rating to be made available sometime around May 14, 2025.
Is the Analyst Rating Terns Pharma (TERN) correct?
While ratings are subjective and will change, the latest Terns Pharma (TERN) rating was a reiterated with a price target of $5.50 to $5.50. The current price Terns Pharma (TERN) is trading at is $8.47, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.